Physician profile
Cristian I Rodriguez Arocho
NPI 1376988873
$227,106.16
in general payments reported to CMS, 2019-2025
51 companies · $44K in 2025
The $44K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,392 · 2020: $2,051 · 2021: $1,965 · 2022: $44K · 2023: $69K · 2024: $64K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Consulting Fee: $27K · Food and Beverage: $11K · Travel and Lodging: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,400 · Honoraria: $2,340 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $118,951.00 |
| Consulting Fee | $27,125.00 |
| Food and Beverage | $11,329.19 |
| Travel and Lodging | $10,302.16 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,400.00 |
| Honoraria | $2,340.00 |
| Education | $159.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $71,933.34 | 2019-2025 | Monjuvi, Monjuvi, Jakafi |
| Genmab U.S., INC. | $29,589.95 | 2023-2025 | Epkinly |
| Alexion Pharmaceuticals, INC. | $25,102.59 | 2021-2025 | Ultomiris, Soliris |
| Abbvie INC. | $22,999.64 | 2021-2025 | Epkinly, Venclexta |
| Sobi, INC | $15,197.00 | 2024-2025 | |
| Cti Biopharma Corp. | $12,714.12 | 2022-2023 | Vonjo |
| Lilly USA, LLC | $11,939.82 | 2022-2024 | Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $8,278.70 | 2019-2025 | Breyanzi, Reblozyl, Pomalyst |
| Seagen INC. | $7,851.37 | 2019-2023 | Adcetris |
| Pfizer INC. | $4,272.75 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $2,713.05 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Adc Therapeutics America, INC. | $2,669.34 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $2,587.25 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Merck Sharp & Dohme LLC | $1,651.76 | 2019-2022 | |
| Amgen INC. | $1,355.09 | 2019-2025 | Blincyto, Kyprolis, Xgeva |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristian Rodriguez Arocho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.